ARTA
ANAB icon

A.R.T. Advisors’s AnaptysBio ANAB Stock Holding History

A.R.T. Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,791
Closed -$832K – 1317
2019
Q3 		$832K Buy
23,791
+17,100
+256% +$814K 0.04% 630
2019
Q2 		$378K Buy
+6,691
New +$482K 0.02% 860
2017
Q4 		– Sell
-14,725
Closed -$514K – 1344
2017
Q3 		$514K Buy
+14,725
New +$397K 0.03% 818

Other funds holding ANAB

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

A.R.T. Advisors's ANAB Position: Q4 2019 in Review

A.R.T. Advisors sold out of AnaptysBio (ANAB) in Q4 2019, closing a stake of 23,791 shares — an estimated $832K sold.

A.R.T. Advisors first reported a position in ANAB in Q3 2017 and held it in 3 quarters. The position peaked at $832K in Q3 2019. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

  • A.R.T. Advisors reported no remaining AnaptysBio position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 23,791 AnaptysBio shares in Q4 2019, an estimated $832K.
  • A.R.T. Advisors first reported a position in AnaptysBio in Q3 2017 and held it in 3 quarters.
  • A.R.T. Advisors's AnaptysBio position peaked at $832K in Q3 2019.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.